-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Shanghai Hengrun Dasheng Biotech Co., Ltd. (hereinafter referred to as "Hangrun Dasheng") announced the completion of 200 million yuan B-plus round of financing.
The current round of financing is funded by investment institutions such as Pudong Science and Technology Group, China New Fund, Wanhui Capital, Dongtai Chongye, XinsiLu Investment, Xinyi Capital, Junjunda Capital and Heng Zhen Partnership.
it is understood that the funds raised by Hengrun Dasheng will be used to support the successful development of its three CAR-T batch of registered clinical trials, to help domestic independent research and development of CAR-T products industrialization, as well as for solid tumors of new targets CAR-T, TCR-T, CAR-NK and solute and other innovative pipeline products research and development.
, as early as 2018, Hengrun Dasheng has completed the A-round and A-plus round of financing, and in 2019 completed another 200 million yuan B-round financing, led by Shenzhen Venture Capital, Maehai Capital and other investment institutions to participate.
Hengrun Dasheng was founded in 2015, the company to cancer immunotherapy technology research and development and application as a breakthrough, simultaneous transformation of the latest tumor immunotherapy technology, and actively promote innovative cancer cell immunotherapy technology development and industrial transformation applications.
As one of the first enterprises in China to enter the cell therapy circuit, Hengrun Dasheng has now formed a research and development pattern led by CAR-T technology, targeting multiple research and development projects such as TCR-T, CAR-NK and lysovirus targeting solid tumors, covering major blood tumors and solid tumor adaptations.
Hengrun Dasheng in the research product pipeline (Source: company official website) Up to now, Hengrun Dasheng has 18 projects for 12 tumor adaptive CAR-T research and development pipeline, of which two have been in the research CAR-T products in China to obtain three clinical batches: 1, research anti-human CD19 T cell injection in China to obtain two clinical trial batches pieces, respectively, for relapsed/refragsive CD19-positive diffuse large B-cell lymphoma and folytic lymphoma, recurring/refractic CD19-positive B-cell acute lymphoblastic leukemia;
It is reported that Hengrun Dasheng in front-end research and development, CMC research, IND declaration, clinical trial development and other aspects of the formation of a sound technical system, hardware supporting aspects, the existing research and development of about 5000 square meters and pilot platform, its located in Zhangjiang Jinshan biomedical base of 11,000 square meters of large-scale CAR-T GMP preparation center is about to be completed, for the future large-scale industrialization of cell products to lay a solid foundation.
International cooperation, Hengrun Dasheng and the United States, Israel, the Czech Republic, Hungary and other countries and other relevant departments and medical institutions reached an agreement to carry out extensive cooperation in CAR-T drug clinical trial research, of which the Israeli Ministry of Health has approved HangRun Dasheng CAR-T products into the country's hospitals to carry out CAR-T drug clinical trial research.
.